Role of Transplant Eligibility in Treating Secondary AML
Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.
Eunice S. Wang, MD, chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia (AML).
Wang emphasizes the importance of considering allogeneic stem cell transplantation for patients with pre-existing bone marrow damage and those who have received extensive prior therapy. These patients, she explains, are unlikely to be cured with further chemotherapy, making early transplantation a critical option.
While transplant was previously not recommended for older patients due to the high risk of acute graft-vs-host disease, advancements in technology and newer drugs have helped mitigate these risks. As a result, allogeneic stem cell transplantation is increasingly being offered to older patients and those without a donor match.
Transcription:
0:10 | It is really important to look at transplant strategies, [especially for patients with] pre-existing damaged bone marrow who have undergone significant prior therapy. These patients are unlikely to be cured with additional cytotoxic chemotherapy alone. The sooner we can get them to an allogeneic stem cell transplant, the better. I think this is a critical point to think about.
0:36 | We also, in the past, had not been recommending that patients go to allogeneic stem cell transplantation due to the high risk, especially in older patients, of developing acute graft-vs-host disease. This is a complication where the donor’s cells attack the host's cells, leading to potential organ failure. However, we now have newer technologies and drugs that help mitigate the high mortality and morbidity associated with acute graft-vs-host disease.
1:08 | So, we are now increasingly able to offer allogeneic stem cell transplantation to older patients and those who, in the past, did not have available donors. We encourage people to consider this option for patients with poor prognosis acute leukemias, including this particular subtype.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
FDA Approves Remestemcel-L in Pediatric Patients With Acute GVHD
December 18th 2024Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
